FDA drafts guidance on best practices for responding to inspection observations
The US Food and Drug Administration (FDA) has released a draft guidance detailing how manufacturers should address Form 483 observations following a drug good manufacturing practice (GMP) inspection. This guidance applies to both domestic and international inspections.The guidance was jointly issued by FDA’s Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Veterinary Medicine (CVM) Office of Inspections and Investigations (OII).
Until now, the FDA has not provided specific guidelines on how to respond to a Form 483. In December 2025, the FDA finalized guidance for companies regarding processes and practices related to bioresearch monitoring (BIMO) violations, which includes responding to a 483. However, this guidance does not address GMP inspections for drugs or biologics. While responding to a 483 is voluntary, not doing so may lead to the FDA issuing a warning letter.
According to an announcement in the Federal Register, FDA has reported receiving inadequate responses to FDA 483 observations. These inadequacies arise from missing or irrelevant data, the inclusion of excessive data, and a failure to address the root cause of observations. FDA said that “poor quality or incomplete responses make it difficult for FDA to ascertain what the establishment has corrected since the inspection and to evaluate remediation activities.”
In its announcement, FDA noted that “the procedures recommended in this draft guidance are intended to help firms understand the significance of the observations, identify root causes, determine risk to patients, and swiftly implement effective corrective actions.’
The guidance specifies that FDA 483 responses should include a table of contents, include the identity of the establishment submitting the response, a copy of the FDA 483 issued at the close of the inspection, and the identity of the response preparer.
Establishments must submit all correspondence in English. If an English translation of a document is provided, a copy of the original document in the foreign language must also be submitted to FDA. This original document should include the translator's name, address, and a brief statement of their qualifications.
FDA said that while establishments are not obligated to respond to the Form 483, the agency recommends that those who choose to respond do so within 15 business days from the date the 483 was issued.
Establishments should assess the severity of each observation and prioritize corrective actions accordingly. This may involve grouping similar issues or adopting a systemic approach to address them. Observations can often be categorized in general areas, such as investigations, cleanrooms, and staff competencies, or by systems, including quality, production, facilities and equipment, packaging and labeling, materials, and laboratory control.
Additionally, establishments should review past inspections and internal audits to identify any repeat observations or emerging trends. Recognizing these categories and trends can reveal systemic issues within a facility or organization. Various quality risk management tools, such as cause-and-effect analysis, can be beneficial in clustering and prioritizing these observations.
If the “responsible official” is not available for discussion when the initial observations were communicated, FDA recommends notifying them about inspectional observations during the inspection. Additionally, they should receive written reports regarding any inspectional observations issued by the FDA. FDA expects that the management of the establishment will review the FDA Form 483 both at the facility level and, if appropriate, at the corporate level. This review should ensure that all relevant personnel are aware of and understand the issues raised during the inspection.
FDA is accepting comments on the draft guidance on www.regulations.gov under docket number FDA-2025-D-1504 through 6 May.
Announcement, Guidance
